Determinants of mTOR inhibitor therapy in AIDS-associated malignancies Public Deposited

Downloadable Content

Download PDF
Creator
  • Sin, Sang-Hoon
    • Affiliation: School of Medicine, Department of Microbiology and Immunology, N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center, UNC Center for AIDS Research
  • Roy, Debasmita
    • Affiliation: School of Medicine, Department of Microbiology and Immunology, N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center, UNC Center for AIDS Research
  • Dittmer, Dirk
    • Affiliation: School of Medicine, Department of Microbiology and Immunology, N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center, UNC Center for AIDS Research
  • Damania, Blossom
    • Affiliation: School of Medicine, Department of Microbiology and Immunology, N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center, UNC Center for AIDS Research
Abstract
  • Rapamycin/Sirolimus™ leads to the regression of transplant- associated Kaposi sarcoma (KS). It also leads to disease stabilization in HIV-associated KS. Case reports and a wealth of preclinical studies support rapamycin’s efficacy also in AIDS associated lymphoma, such as primary effusion lymphoma (PEL). Rapamycin inhibits the mammalian target of rapamycin (mTOR) and papamycin derivatives are approved for the treatment of mantle cell lymphoma and other cancers. It is not universally effective against all solid tumors. Even within this group of clinically responsive cancers, there are exceptions of cases or cell models in which this drug or its derivatives (rapalogs) fail.
Date of publication
Identifier
  • doi:10.1186/1750-9378-7-S1-O9
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • Dirk P Dittmer et al.; licensee BioMed Central Ltd.
License
Journal title
  • Infectious Agents and Cancer
Journal volume
  • 7
Journal issue
  • Suppl 1
Page start
  • O9
Language
  • English
Is the article or chapter peer-reviewed?
  • Yes
ISSN
  • 1750-9378
Bibliographic citation
  • Infectious Agents and Cancer. 2012 Apr 19;7(Suppl 1):O9
Access
  • Open Access
Publisher
  • BioMed Central Ltd
Parents:

This work has no parents.

Items